Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs

Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs Publisher

Salehbayat M¹ ; Abolfazli R² ; Mohebbi N^{3, 4} ; Savar SM⁴ ; Shalviri G⁴ ; Gholami K^{3, 4}

Source: Basic and Clinical Neuroscience Published:2023

Abstract

Introduction: High frequency of adverse drug reactions (ADRs) challenges multiple sclerosis (MS) treatment. This study aims to assess the nature and frequency of ADRs induced by MS medications in an observational cross-sectional study. Methods: ADRs of all outpatients who had seen a neurologist and had received at least one disease-modifying therapy (DMT) for MS during the last three months were investigated. Results: A total of 484 ADRs were detected in these patients. The preventability rate was 5.9%, and 0.61% of reactions were serious. Conclusion: The high frequency of adverse drug reactions in this study shows a strong need for strategy planning to increase patients’ adherence to treatment. © 2023 Iran University of Medical Sciences. All rights reserved.

Related Docs

View other Related Docs

1. The Efficacy and Safety of Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2020)

2. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)

3. Current and Future Trends in Multiple Sclerosis Management: Near East Perspective, Multiple Sclerosis and Related Disorders (2023)

Experts (# of related papers)

View all Related Experts

Mohammad Ali Sahraian (8)

Amirreza Azimi (3)

Style	Citing Format
MLA	Salehbayat M, et al.. "Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs." Basic and Clinical Neuroscience, vol. 14, no. 6, 2023, pp. 879-884.
APA	Salehbayat M, Abolfazli R, Mohebbi N, Savar SM, Shalviri G, Gholami K (2023). Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs. Basic and Clinical Neuroscience, 14(6), 879-884.
Chicago	Salehbayat M, Abolfazli R, Mohebbi N, Savar SM, Shalviri G, Gholami K. "Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs." Basic and Clinical Neuroscience 14, no. 6 (2023): 879-884.
Harvard	Salehbayat M et al. (2023) 'Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs', Basic and Clinical Neuroscience, 14(6), pp. 879-884.
Vancouver	Salehbayat M, Abolfazli R, Mohebbi N, Savar SM, Shalviri G, Gholami K. Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs. Basic and Clinical Neuroscience. 2023;14(6):879-884.
BibTex	@article{ author = {Salehbayat M and Abolfazli R and Mohebbi N and Savar SM and Shalviri G and Gholami K}, title = {Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs}, journal = {Basic and Clinical Neuroscience}, volume = {14}, number = {6}, pages = {879-884}, year = {2023} }
RIS	TY - JOUR AU - Salehbayat M AU - Abolfazli R AU - Mohebbi N AU - Savar SM AU - Shalviri G AU - Gholami K TI - Adverse Drug Reactions of Multiple Sclerosis Diseasemodifying Drugs JO - Basic and Clinical Neuroscience VL - 14 IS - 6 SP - 879 EP - 884 PY - 2023 ER -

Science Communicator Platform

Authors

Abstract